These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 17433696)

  • 1. Scaffold hopping, synthesis and structure-activity relationships of 5,6-diaryl-pyrazine-2-amide derivatives: a novel series of CB1 receptor antagonists.
    Boström J; Berggren K; Elebring T; Greasley PJ; Wilstermann M
    Bioorg Med Chem; 2007 Jun; 15(12):4077-84. PubMed ID: 17433696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel thioamide derivatives as neutral CB1 receptor antagonists.
    Boström J; Olsson RI; Tholander J; Greasley PJ; Ryberg E; Nordberg H; Hjorth S; Cheng L
    Bioorg Med Chem Lett; 2010 Jan; 20(2):479-82. PubMed ID: 20005704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and pharmacological evaluation of novel octahydro-1H-pyrido[1,2-a]pyrazine as mu-opioid receptor antagonists.
    Le Bourdonnec B; Goodman AJ; Graczyk TM; Belanger S; Seida PR; DeHaven RN; Dolle RE
    J Med Chem; 2006 Dec; 49(25):7290-306. PubMed ID: 17149859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis and biological evaluation of piperazine analogues as CB1 cannabinoid receptor ligands.
    Song KS; Lee SH; Chun HJ; Kim JY; Jung ME; Ahn K; Kim SU; Kim J; Lee J
    Bioorg Med Chem; 2008 Apr; 16(7):4035-51. PubMed ID: 18243711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diarylimidazolyl oxadiazole and thiadiazole derivatives as cannabinoid CB1 receptor antagonists.
    Kim JY; Seo HJ; Lee SH; Jung ME; Ahn K; Kim J; Lee J
    Bioorg Med Chem Lett; 2009 Jan; 19(1):142-5. PubMed ID: 19022666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Keynote review: Medicinal chemistry strategies to CB1 cannabinoid receptor antagonists.
    Lange JH; Kruse CG
    Drug Discov Today; 2005 May; 10(10):693-702. PubMed ID: 15896682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel 3,4-diarylpyrazolines as potent cannabinoid CB1 receptor antagonists with lower lipophilicity.
    Lange JH; van Stuivenberg HH; Veerman W; Wals HC; Stork B; Coolen HK; McCreary AC; Adolfs TJ; Kruse CG
    Bioorg Med Chem Lett; 2005 Nov; 15(21):4794-8. PubMed ID: 16140010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemical and biological investigation of cyclopropyl containing diaryl-pyrazole-3-carboxamides as novel and potent cannabinoid type 1 receptor antagonists.
    Szabó G; Varga B; Páyer-Lengyel D; Szemzo A; Erdélyi P; Vukics K; Szikra J; Hegyi E; Vastag M; Kiss B; Laszy J; Gyertyán I; Fischer J
    J Med Chem; 2009 Jul; 52(14):4329-37. PubMed ID: 19527048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biarylpyrazolyl oxadiazole as potent, selective, orally bioavailable cannabinoid-1 receptor antagonists for the treatment of obesity.
    Lee SH; Seo HJ; Lee SH; Jung ME; Park JH; Park HJ; Yoo J; Yun H; Na J; Kang SY; Song KS; Kim MA; Chang CH; Kim J; Lee J
    J Med Chem; 2008 Nov; 51(22):7216-33. PubMed ID: 18954042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, biological evaluation, and comparative docking study of 1,2,4-triazolones as CB1 receptor selective antagonists.
    Han S; Zhang FF; Xie X; Chen JZ
    Eur J Med Chem; 2014 Mar; 74():73-84. PubMed ID: 24445310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and SAR of 1,4,5,6-tetrahydropyridazines as potent cannabinoid CB1 receptor antagonists.
    Lange JH; den Hartog AP; van der Neut MA; van Vliet BJ; Kruse CG
    Bioorg Med Chem Lett; 2009 Oct; 19(19):5675-8. PubMed ID: 19699640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of pyrazine carboxamide CB1 antagonists: the introduction of a hydroxyl group improves the pharmaceutical properties and in vivo efficacy of the series.
    Ellsworth BA; Wang Y; Zhu Y; Pendri A; Gerritz SW; Sun C; Carlson KE; Kang L; Baska RA; Yang Y; Huang Q; Burford NT; Cullen MJ; Johnghar S; Behnia K; Pelleymounter MA; Washburn WN; Ewing WR
    Bioorg Med Chem Lett; 2007 Jul; 17(14):3978-82. PubMed ID: 17513109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diaryl piperidines as CB1 receptor antagonists.
    Scott JD; Li SW; Wang H; Xia Y; Jayne CL; Miller MW; Duffy RA; Boykow GC; Kowalski TJ; Spar BD; Stamford AW; Chackalamannil S; Lachowicz JE; Greenlee WJ
    Bioorg Med Chem Lett; 2010 Feb; 20(3):1278-83. PubMed ID: 20018510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Studies on pyrazine derivatives. XLVII. Synthesis and antibacterial activity of novel pyrazine derivatives with amidoxime moiety.
    Gobis K; Foks H; Kedzia A; Wierzchowska M; Kwapisz E; Zwolska Z; Augustynowicz-Kopeć E
    Acta Pol Pharm; 2006; 63(1):39-45. PubMed ID: 17515328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of 1-[9-(4-chlorophenyl)-8-(2-chlorophenyl)-9H-purin-6-yl]-4-ethylaminopiperidine-4-carboxylic acid amide hydrochloride (CP-945,598), a novel, potent, and selective cannabinoid type 1 receptor antagonist.
    Griffith DA; Hadcock JR; Black SC; Iredale PA; Carpino PA; DaSilva-Jardine P; Day R; DiBrino J; Dow RL; Landis MS; O'Connor RE; Scott DO
    J Med Chem; 2009 Jan; 52(2):234-7. PubMed ID: 19102698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and c-Src inhibitory activity of imidazo[1,5-a]pyrazine derivatives as an agent for treatment of acute ischemic stroke.
    Mukaiyama H; Nishimura T; Kobayashi S; Ozawa T; Kamada N; Komatsu Y; Kikuchi S; Oonota H; Kusama H
    Bioorg Med Chem; 2007 Jan; 15(2):868-85. PubMed ID: 17095233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploring SAR features in diverse library of 4-cyanomethyl-pyrazole-3-carboxamides suitable for further elaborations as CB1 antagonists.
    Cooper M; Receveur JM; Bjurling E; Nørregaard PK; Nielsen PA; Sköld N; Högberg T
    Bioorg Med Chem Lett; 2010 Jan; 20(1):26-30. PubMed ID: 19954978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insights into the molecular requirements for the anti-obesity activity of a series of CB1 ligands.
    Weber KC; De Lima EF; De Mello PH; Da Silva AB; Honório KM
    Chem Biol Drug Des; 2010 Oct; 76(4):320-9. PubMed ID: 20887613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-activity studies on diphenylpyrazine derivatives: a novel class of prostacyclin receptor agonists.
    Asaki T; Hamamoto T; Sugiyama Y; Kuwano K; Kuwabara K
    Bioorg Med Chem; 2007 Nov; 15(21):6692-704. PubMed ID: 17764960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of novel cannabinoid CB1 receptor antagonists by using virtual screening with a pharmacophore model.
    Wang H; Duffy RA; Boykow GC; Chackalamannil S; Madison VS
    J Med Chem; 2008 Apr; 51(8):2439-46. PubMed ID: 18363352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.